glp-1 and kidneys Glucagon-like Peptide-1 Receptor Agonists Diabetic Kidney Disease: From Bench to Bed-Side GLP-1 Medications & Their Potential

Retatrutide is still in the middle of its phase 3 trial program

Retatrutide has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), and no marketing authorisation application has been approved as of the date of publication of this article

O'Reilly MW, House PJ, Tomlinson JW

GLP-1 RA microdosing uses doses below the smallest available commercial threshold typically starting at 0.1250.25 mg semaglutide weekly and often extends dosing intervals to every 10, 14, 21, or 28 days

The overall cardiovascular risk profile improves meaningfully

Am J Chin Med